miRNAs as predictive biomarkers of response to treatment in pediatric patients with acute lymphoblastic leukemia

• Published in: Oncology letters Vol. 27; no. 2; p. 1
• Main Authors: Tsotridou, Eleni, Georgiou, Elisavet, Tragiannidis, Athanasios, Avgeros, Chrysostomos, Tzimagiorgis, Georgios, Lambrou, Maria, Papakonstantinou, Eugenia, Galli-Tsinopoulou, Assimina, Hatzipantelis, Emmanouel
• Format: Journal Article
• Language: English
• Published: Spandidos Publications 01.02.2024
• Subjects: Acute lymphocytic leukemia; Biological markers; Cancer; Care and treatment; Children; Computer industry; Corticosteroids; Epigenetic inheritance; Ethylenediaminetetraacetic acid; Health aspects; Medical colleges; MicroRNA; Oncology, Experimental; Pediatrics; Prednisone; Prognosis; Vincristine; Greece; United States
• ISSN: 1792-1074
• DOI: 10.3892/01.2023.14204

MicroRNAs (miRNAs/miRs) are promising prognostic biomarkers in pediatric acute lymphoblastic leukemia (ALL). The present study aimed to identify miRNAs that could serve as prognostic biomarkers or as novel therapeutic targets in ALL. The expression levels of 84 miRNAs were assessed in the bone marrow aspirates of 10 pediatric patients with newly diagnosed ALL at diagnosis and on day 33 of induction of the ALL Intercontinental Berlin-Frankfurt-Munster 2009 protocol, and associations with established prognostic factors were evaluated. The levels at diagnosis of 25 miRNAs were associated with [greater than or equal to]2 prognostic factors. Higher expression levels of let-7c-5p, miR-106b-5p, miR-26a-5p, miR-155-5p, miR-191-5p, miR-30b-5p and miR-31-5p were significantly associated with a good prednisone response. The expression levels of miR-125b-5p, miR-150-5p and miR-99a-5p were significantly higher in standard- or intermediate-risk patients compared with those in high-risk patients (P=0.017, P=0.033 and P=0.017, respectively), as well as in those with a complete response at the end of induction (P= 0.044 for all three miRNAs). The change in expression levels between diagnosis and the end of induction differed significantly between risk groups for three miRNAs: miR-206, miR-210 and miR-99a (P=0.033, P=0.047 and P=0.008, respectively), with the post induction levels of miR-206 increased in high-risk patients, whilst miR-210 and miR-99a levels were increased in intermediate/standard risk patients. Therefore, miRNAs that could be integrated into the risk stratification of pediatric ALL after further evaluation in larger patient cohorts were identified. Key words: microRNAs, acute lymphoblastic leukemia, pediatrics, prognosis, epigenetics